Research groups
Pramila Rijal
DPhil
RDM Principal Investigator
- COI Career Development Fellow
Antibody Discovery, Viral Immunology and Vaccine Development
Dr. Pramila Rijal specialises in viral immunology, human monoclonal antibody discovery, and vaccine development, with a particular focus on understanding protective antibody responses and translating these insights into improved strategies against infectious diseases. She obtained her DPhil from the University of Oxford in 2017 under the supervision of Professor Alain Townsend, investigating human antibody responses to influenza and Ebola viruses following natural infection and vaccination.
With over a decade of research experience, Dr. Rijal has made important contributions to understanding the molecular basis of protective antibody responses and their implications for viral evolution, vaccine design, and antibody-based therapeutics. Her doctoral research contributed to demonstrating how highly focused antibody responses can exert selective pressure on influenza viruses, promoting antigenic drift. Her subsequent research has included the discovery and characterisation of broadly inhibitory human monoclonal antibodies against influenza neuraminidase and the development of therapeutic antibody candidates targeting Ebola virus.
Dr. Rijal has also contributed to the development of single-cycle influenza vaccines (S-FLU), the investigation of influenza-specific antibody responses in porcine models, and collaborative studies of SARS-CoV-2 immunity during the COVID-19 pandemic. These studies have encompassed antibody discovery, functional and structural characterisation, viral neutralisation, serological assay development, and vaccine evaluation.
Her current research focuses on understanding antibody recognition of influenza neuraminidase (NA), identifying conserved antigenic vulnerabilities, and developing improved NA-based vaccines and antiviral strategies. Her recent work has demonstrated how structure-guided antigen engineering can improve the expression and stability of influenza neuraminidase while retaining important antigenic properties, providing new opportunities for rational vaccine design.
Through her independent research programme, Dr. Rijal aims to integrate fundamental discoveries in human antibody biology with translational approaches to develop broader and more effective interventions against influenza and other emerging viral pathogens.
Recent publications
Porcine influenza mAbs to H3, H5, and H7 hemagglutinins recognize H3 egg adapted site and target the HA stem.
Journal article
Cayol T. et al, (2026), Discov Immunol, 5
Structure-guided loop grafting improves expression and stability of influenza neuraminidase for vaccine development.
Journal article
Rijal P. et al, (2025), Elife, 14
Structure-guided loop grafting improves expression and stability of influenza neuraminidase for vaccine development
Journal article
Rijal P. et al, (2025), eLife, 14
A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
Journal article
Sadler HL. et al, (2025), J Virol, 99
A review of broadly protective monoclonal antibodies to treat Ebola virus disease.
Journal article
Rijal P. and Donnellan FR., (2023), Curr Opin Virol, 61